Perrigo appoints two new independent directors to board
Mr. Parker's appointment was effective November 7, 2016, while Mr. Samuels will join the Board on January 4, 2017 after his expected retirement from Capital Group.
Mr. Parker will join the Audit Committee.
Mr. Parker currently serves as a member of the board of directors of Genomic Health, Sunesis Pharmaceuticals and ChemoCentryx.
Mr. Parker previously served as Chief Financial Officer of Anacor Pharmaceuticals from September 2010 to May 2015.
From 1997 to 2009, Mr. Parker led the West Coast Healthcare Investment Banking practice at Goldman Sachs, where he advised leading companies in the biotechnology, life science tools and medical device industries.
He holds an A.B. degree in Economics and Engineering Science from Dartmouth College and an MBA from the Stanford Graduate School of Business.
Mr. Samuels has served as President of Capital Guardian Trust Company, a Capital Group company, since 2010 and an equity portfolio manager and investment analyst at Capital Group since 1981.
Mr. Samuels has evaluated numerous companies across all sectors and has served on many management and investment committees, with an eye toward shareholder value creation.
He holds a B.A. from Harvard College and an MBA from Harvard Business School.
Additionally, current Perrigo board members Michael Jandernoa and Gary Kunkle have elected to not stand for reelection in 2017. ■
What to read next
LATEST MOVES FROM United Kingdom
- Town Centre Securities appoints Mark Dilley as finance director
- Plus500 promotes Penelope Judd to chairman
- IGas Energy appoints two to board
- EVR Holdings appoints Ian Hanson as director
- Morgan Sindall Group appoints Tracey Killen as director
More inside POST
Monsanto Q2 EPS reached $3.09 Earnings